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Animal venoms comprise a naturally selected cocktail of bioactive peptides/proteins and other molecules, each of which playing
a defined role thanks to the highly specific interactions with diverse molecular targets found in the prey. Research focused on
isolation, structural, and functional characterizations of novel natural biologics (bioactive peptides/proteins from natural sources)
has a long way to go through from the basic science to clinical applications. Herein, we overview the structural and functional
characteristics of the myoneurotoxin crotamine, firstly isolated from the South American rattlesnake venom. Crotamine is the first
venompeptide classified as a natural cell penetrating and antimicrobial peptide (CPP andAMP)with amore pronounced antifungal
activity. In contrast to other known natural CPPs and AMPs, crotamine demonstrates a wide spectrum of biological activities with
potential biotechnological and therapeutic values. More recent studies have demonstrated the selective in vitro anticancer activity
of crotamine. In vivo, using a murine melanoma model, it was shown that crotamine delays tumor implantation, inhibits tumor
cells proliferation, and also increases the survival of mice engrafted with subcutaneous melanoma. The structural and functional
properties and also the possible biotechnological applications of minimized molecules derived from crotamine are also discussed.
1. Introduction
Snake venoms contain a complex cocktail of toxins (proteins
and enzymes), which are designed to assault the cardiovas-
cular system (hemotoxic), to target specific tissues or muscle
types (cytotoxic), and to go directly into the brain and nerv-
ous system (neurotoxic) of the prey. Crotamine, which is one
of themajor components of the venomof the SouthAmerican
rattlesnake Crotalus durissus terrificus, combines the cyto-
toxic and neurotoxic properties. Crotamine is a low molec-
ular weight, nonenzymatic, and noncytolytic small protein,
composed of about 42 amino acid residues. Among them,
11 are basic amino acid residues (nine lysines and two argi-
nines), and six are cysteine residues that form three disulfide
bridges [1]. These basic amino acids provide a highly positive
charge for this peptide. Crotamine has two isoforms found in
different subspecies, and they differ by the presence of an iso-
leucine residue in position 19 instead of leucine.The 3D solu-
tion structure of crotamine was determined by proton NMR
spectroscopy [1], showing that crotamine structure encom-
passes a short N-terminal 𝛼-helix (involving the residues 1–
7), two stranded anti-parallel 𝛽-sheets (residues 9–13 and
34–38), and two 𝛽-turns (residues 14–16 and 27–34). Conse-
quently, it was suggested that the toxin is arranged in𝛽
1
𝛼𝛽
2
𝛽
3
topology, where both the first and second strands run antipar-
allel to the third one, while the 𝛽-sheet twisted in a right-
handed fashion. this 𝛽-sheet is stabilized by four hydrogen
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Figure 1: The crotamine derived peptide NrTP1 structure. NrTP1
synthetic peptide combines theN- andC-terminus of crotamine and
embraces the first nine residues that are linked to the last residues
38–42, which are depicted in black in structure of the crotamine
molecule above. NrTP1 and analogues are capable of membrane
translocating and they localize in the nucleolus of tumor cells.
Crotamine structure contains 42 residues arranged in a topology
𝛼𝛽
1
𝛽
2
: one 𝛼-helix with residues 1–7 and two-stranded antiparallel
𝛽-sheets with residues 9–13 and 34–38.The structure is stabilized by
three disulfide bridges C
4
–C
36
; C
11
–C
30
; C
18
–C
37
[1, 2]. This figure
was adapted from [5].
bonds between the strands 𝛽
1
and 𝛽
3
, (extending from the
residues 10–37 and 12–35) and by other two hydrogen bonds
between the strands 𝛽
2
and 𝛽
3
(residues 25–36). However,
soon later, other authors described the presence of only two
𝛽-sheets [2], which is in accordance with others [3, 4]. Inter-
chain disulfide bonds promote protein cross-linking (Cys4–
Cys36, and Cys18–Cys37) between the strand 𝛽
3
with the 𝛼-
helix and the first loop (Pro13–Ser23), respectively, while the
Cys11–Cys30 bond promotes the connection of 𝛽
1
-sheet with
the second loop (Gly26–Trp34) [1, 4] (Figure 1, Table 1).
1.1. Genomic Structure and Chromosomal Localization of the
Gene for Crotamine. In the Crotalus genus, which belongs to
the Viperidae family, the karyotype is composed of 36 chro-
mosomes: eight macrochromosome and ten microchromo-
some pairs. The sex determining system in this genus is het-
eromorphic in females (ZZ/ZW), and the fourth pair of mac-
rochromosomes is the sex pair [7]. Fluorescent in situ
hybridization (FISH) revealed that crotamine gene is local-
ized at the end of the long arm of chromosome 2. How-
ever, the consistent difference in the intensity of the FISH
signals between homologous chromosomes was evidenced,
suggesting a variable number of copies of the gene on each
chromosome [8].This in turnwould be a possible explanation
for the variable amounts of crotamine found in the venom of
crotamine-positive C. d. terrificus [9–11].
1.2. Crotamine Cytotoxicity. Toxins, by definition, are effec-
tive and specific poisonous bullets produced by the living
organisms. The biological activities of crotamine were tested
by intraperitoneal (IP) injection into mice in sublethal doses
corresponding to 2.5mg of toxin/kg body mass, which pro-
vokes the hind limb paralysis and the necrosis of the muscle
cells ofmice [9]. In vitro, at final concentration 10 𝜇g/mL, cro-
tamine was demonstrated to be toxic for muscles cells, pro-
moting muscle tissue necrosis [10, 11]. In contrast, crotamine,
at final concentration ranging from 1 to 10 𝜇g/mL, was not
cytotoxic to other normal cells of different types (e.g., human
and mouse fibroblasts, muscle cells, human endothelial cells
(HUVEC), lymphoblast (immortalized lymphocytes), mouse
3T3 cells line,mouse embryonic stem (mES) cells and others),
even after 72 h of exposure [12].
1.3. Cell Penetrating Activity of Crotamine. Cell penetrating
peptides (CPPs) are a class of bioactivemolecules, also known
as protein transduction domains (PTDs), membrane translo-
cating sequences (MTSs), and Trojan peptides [13]. They are
short peptides (usually ≤40 amino acid residues), with the
ability to gain the access into the inner side of almost any cell
[13]. Crotamine similar to other CPPs showed a rapid translo-
cation (within 5min) into all cell types investigated up to now
[12]. Distinctly from other CPPs, crotamine demonstrates a
preferential and expressive accumulation in actively prolifer-
ating cells [12]. Some CPPs show nuclear localization, as well
as crotamine. Interestingly, in the nucleus, it binds to chro-
mosomes and centrioles during the cell division. In meta-
phase chromosomes, fluorescently labeled crotamine binding
to the chromosome produces a specific banding pattern,
which is different from that presented by known DNA inter-
calation dyes, such as those that allow observing the G-
banding or Giemsa banding and others such as the fluores-
cent stain 4󸀠,6-diamidino-2-phenylindole (DAPI), which are
commonly used in cytogenetic to produce a visible karyotype
by staining condensed chromosomes [12]. The double helix
of DNA is highly and negatively charged due to all the
negatively charged phosphates in the backbone. Our recent
study reported that positively charged crotamine binds non-
cooperatively to negatively charged DNA, covering about 5
nucleotide residues when it connects to a single or double
stranded molecules [14]. Our data suggest that specific band-
ing pattern observed on chromosomes results from electro-
static interaction between DNA phosphates and crotamine.
This intrinsic biophysical property also distinguishes cro-
tamine from other CPPs [15]. In vivo, crotamine penetrates
into mice tissues, such as liver, skeletal muscle, bone marrow,
and kidney [16]. Crotamine also crosses the blood-brain
barrier (BBB), as the fluorescently labeled crotamine [16] as
well as the radiolabeled form [17] was found in the brain.
Three steps for the transcytosis of crotamine through the BBB
can be suggested: (1) binding and internalization through
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Table 1: Crotamine main characteristics, properties, and potential biotechnological applications∗.
Name Crotamine
Organism Crotalus durissus terrificus South American rattlesnakeCommon name: Cascavel
Taxon authority [6]
Geographic range Brazil, Peru, Bolivia, Paraguay, Uruguay, Argentina∗
Classification Myoneurotoxin, cell-penetrating peptide, antimicrobial peptide, and defensin-like peptide
Molecular weight 4726,63 daltons
Isoelectric point pI 9.54, highly positive
Length Polypeptide of 42 amino acids
Primary sequence KQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG
Isoform Crotamine-Ile 19 (isoleucine substitution at position 19)∗
Chemical formula C346H530N90O82S8 (isoform 1)
∗
Solubility Highly soluble in water and physiological solutions
Stability Highly stable in solution, relative large pH range, and temperature
Folding Crotamine is arranged in a 𝛼𝛽1𝛽2 topology stabilized by 3 disulfide bridges: an 𝛼-helix withresidues 1–7 and a two-stranded antiparallel 𝛽-sheets with residues 9–13 and 34–38.
Disulfide bonds C4–C36; C11–C30; C18–C37
Physiological and neurological activity Hind limb paralysis in mice in final concentration 2.5mg of toxin/kg body massNecrosis of muscle cells
Electrophysiology activity Mammalian Kv1.1, Kv1.2, and Kv1.3 blocker with IC(50) of 286.53 ± 91.72 nM
In vitro toxicity (normal cells) Nontoxic (concentration ranged from 0.1 to 10 𝜇M)
Embryotoxicity Nontoxic (concentration ranged from 0.1 to 10 𝜇M)
Cell penetrating activity (in vitro) Selective: dividing (actively proliferating cells)Concentration, cell type, and cell-cycle dependent
Intracellular localization Cytosol, vesicles, nucleus, centrioles, and chromosomes
Mechanism of DNA-crotamine
interaction Only electrostatic: crotamine (+charged)—DNA (−charged) aggregate
Uptake Within 5 minutes, and permanence in the cells for approximately 24 hours
Mechanism of penetration Membrane heparan sulfate proteoglycans binding and clathrin-dependent endocytosis
Cell penetrating activity (in vivo) Selective: dividing (actively proliferating cells), for example stem cells in bone marrow, spleen,liver, lung, and so force.
Localization in brain Able to cross blood-brain barrier, and localization in brain cells
Molecular carrier Intracellular delivery of DNA (both circular and linear molecules) in vivo and in vitro. Finalcomplex size dependent delivery.
Antimicrobial activity
Modest against Gram-positive and Gram-negative bacteria, with some exceptions, for example
Micrococcus luteus, and with no detectable activity against the filamentous fungus Aspergillus
fumigatus and Trichophyton rubrum at concentrations up to 125𝜇g/mL.
Antimycotic (-fungal) activity Significant activity against yeast Candida spp.
Cancer cells toxicity Toxic (concentration ranged from 0.1 to 10 𝜇M)Inoffensive for normal cells
Anticancer activity (in vitro) Strong against melanoma cells in vitro
Anticancer activity (in vivo) Inhibition and delay of melanoma growth in vivo in mouse model
Mechanism of tumor inhibition Mitochondrial depolarizationIntracellular calcium release
Immunogenicity Low
Biotechnological and biomedical
applications
Marker of centrioles and cell cycle; marker of actively proliferating normal cells; biomolecules
carrier; tool for cancer cells investigation; marker of cancer cells in vitro and in vivo, and as
antifungal and anticancer agent. Prototype for new drug design.
∗Several old data about crotamine need to be revised using modern approaches.
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Figure 2: Crotamine action in normal (red) and cancer (blue) cells. Crotamine is a positively charged (blue) protein. In normal cells,
crotamine uptake occurs through clatrin-dependent endocytosis followed by lysosome accumulation, followed by its release in the cytosol due
to the disruption of the vesicles containing crotamine. In normal cells, crotamine interacts electrostatically with centrioles and chromosomes
and can be used as a biotechnological tool, as carrier of bioactive molecules, and as a marker of cell cycle. Cancer cells, which have more
negatively charged molecules on their surface compared to normal cells, potentially attract crotamine strongly. In cancer cells, crotamine
intracellular concentration appears to be higher than that observed in normal cells, thus probably leading to cell lyses and cell death. In
cancer cells, crotamine inhibits tumor growth and kills tumor cells, besides representing a potential tool for in vivo cancer cells identification.
endocytosis at the luminal side of endothelial cell membrane,
which is negatively charged due to the presence of chon-
droitin and heparan sulfate molecules, (2) CPPs diffusion via
the cytoplasm, and (3) externalization from endothelial cells
[18, 19]. All these pathways are in accordance to the previously
described mechanism of crotamine intracellular penetration
[20].
1.4. Crotamine-Targeted Delivery of Plasmid DNA. The com-
mon feature among the CPPs is their capacity to deliver bio-
logically active molecules into the cells both in vitro and in
vivo. The majority of CPPs do not present any cell specificity
for the translocation into the cells [21]. In contrast, crotamine
displays specificity for actively proliferating cells, even when
employed as gene delivery agent [16, 20]. This feature of
crotamine could be advantageous to allow for an efficient and
selective transfection of rapidly dividing cells, for example,
normal stem cells, without strongly affecting the cell viability,
and cancer stem cells in contrast to the currently widely used
procedure, such as electroporation that causes the death of
about 90% of the cells [22]. In addition, crotamine provides a
successful in vivo transfection of bone marrow (BM) cells of
mice after IP injection of crotamine-pEGFP-N1 plasmidDNA
complex [16]. The proportion of BM cells displaying GFP
fluorescence (about 10–20% of total) is in good agreement
with the described ratio of proliferating cells present in the
BM tissue.TheGFPfluorescent signal was also detected in the
liver and lung cells of mice [16]. In other words, the observed
crotamine-mediated transfection in vivo [16] is similar to the
previously described in vitro selectivity [12].
1.5. Mechanism of Crotamine Penetration and Cargo Deliv-
ery into Cells. Using pharmacological inhibitors and low-
temperature conditions,we also demonstrated that crotamine
internalization is dependent of endocytosis. Its penetration
was decreased by 92.3% in the presence of chloroquine
[23], which disrupts endosomal pathway by interfering with
the acidification of the endosome, due to the inhibition of
ion-transporting ATPase. Additionally, crotamine partially
relied on the clathrin-dependent pathway for the cell uptake,
since chlorpromazine (an inhibitor of clathrin mediated
endocytosis) inhibited crotamine penetration by 65%. The
inhibition of lipid rafts (dynamic microdomains of choles-
terol, sphingolipids, and proteins clusters of the membrane)
endocytosis, and alsomacropinocytosis did not interferewith
crotamine internalization. On the other hand, low temper-
ature (4∘C) affected negatively the cell uptake of crotamine,
since the efficiency of internalization could be drastically
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reduced showing the retention of the crotamine on the cell
surface [17].
2. Crotamine Derived Peptides
2.1. CyLoP-1. The nuclear translocation process resides on
lysine- and arginine-rich nuclear localization signals (NLSs).
Kerkis and coworkers [12] suggested that crotamine has two
putative NLS motifs, Crot
2–18 (KQCHKKGGHCFPKEKIC)
and Crot
27–39 (KMDCRWRWKCCKK), which could be
responsible for crotamine nuclear localization. The syn-
thesis of one of such NLS motifs as thetridecapeptide
Crot
27–39 (KMDCRWRWKCCKK), which included 3 cys-
teine residues, and one tryptophan, aspartic acid, andmethio-
nine, along with 6 basic amino acid residues (arginine and
lysine) has also been reported by Jo¨rn Engelmann group
from Germany that named this synthetic peptide as CyLoP-1
(Cytosol Localizing Peptide-1) [24]. The cell uptake of this
peptide coupled to FITC presents in NIH-3T3 cell line
mainly cytosol localization, instead of a nuclear distribution
pattern. In order to determine the optimal length for the cell
penetrating properties, single deletions of the residues from
the N-terminus of CyLoP-1 have been done. Newly produced
CyLoP-1 derived peptide 4 (CRWRWKCCKK) demonstrated
about 20% higher cellular uptake efficiency compared to the
CyLoP-1, and the best homogeneous distribution in the cell
cytosol was found for this CyLoP-1 derived peptide 4. Inter-
estingly, peptide 4 was found to be uniformly distributed in
the cytoplasm alongwith an endosomal and vesicular fluores-
cence localization. The substitution of one to three cysteines
by serine residue(s) led to the loss in the uptake efficiency
of CyLoP-1 derived peptide 4. Based on the intracellular dis-
tribution pattern observed for this peptide, such as the per-
inuclear localization of the peptide, vesicles-filled fluores-
cent, or the cytosolic spread in different cell types, the
authors concluded that, at least, CyLoP-1 derived peptide 4
uptake and its cytosolic distribution is dependent on
the cell type. The carrier ability of CyLoP-1 was com-
pared to other well-characterized CPPs, namely, Tat, pene-
tratin, and octaarginines. D-Tat
49–57 (RKKRRQRRR) and D-
octaarginine (RRRRRRRR) and penetratin (RQIKIWFQNR-
RMKWKK) are also highly cationic. In addition, penetratin
andCyLoP-1 derived peptide 4 (CRWRWKCCKK) are rich in
hydrophobic residues. Long-term incubation of these CPPs
[2.5 𝜇M] showed a lower cellular internalization in com-
parison to the CyLoP-1 derived peptide 4 [24]. Albeit, the
same CPPs composed of D-amino acid residues showed an
increased cell uptake. Indeed, the CyLoP-1 derived peptide
4, composed of L-amino acid residues was found to be the
most efficient CPP for a long-term labeling [24]. Moreover,
similarly to crotamine, the uptake of CyLoP-1 derived peptide
4 is strongly dependent on the cell type. Successful delivery
of cargoes by CyLoP-1 also depends on their sizes. The differ-
ences in sizes and charge hydrophobicity or function of cargos
in the delivery of resulting conjugates formed with CyLoP-
1 derived peptide 4 were evaluated in NIH-3T3 cell line,
after 18 h incubation, using the concentration of 2.5𝜇M. As
expected, the increase in molecular size resulted in an overall
decrease in the intracellular uptake [24].
2.2. Nucleolar-Targeting Peptides (NrTPs). It has been
reported that the native crotamine also targets nucleolus,
which is a nuclear structure composed by RNA, DNA, and
proteins, that has different functions, such as ribosomal sub-
unit assembly, mRNA biogenesis, and nucleolus organizer
region, in immortalized and cancer cell lines, such as CHO
(Chinese hamster ovary) and murine melanoma B16-F10
[16]. Ra´dis-Baptista and coworkers [5] designed and synthe-
sized the nucleolar-targeting peptides (NrTPs) based on
two structural simplified sequences of crotamine:
Peptide 1 (YKQCHKKGGKKGSG) and Peptide 2
(YKQCHKKGGXKKGSG), both containing only one single
cysteine residue (Figure 1). In HeLa cells, they were found at
the nucleus and in nucleolus. Similarly to the native crota-
mine, these peptides bind to DNA and chromosomes at dif-
ferent stages of the cell cycle [15].
3. Crotamine Antimicrobial and
Antifungal Activity
The antimicrobial peptides (AMPs) are small cationic pep-
tides, responsible for the adaptive immunity in the external
surface of skin and mucus of several organisms across the
evolutionary spectrum [25]. The AMPs are a unique class
composed of varying molecules grouped into subgroups
based on their amino acid composition and structure. AMPs
are classified into three major groups: (i) peptides with an 𝛼-
helical conformation (insect cecropins, magainins, etc.), (ii)
cyclic and open-ended cyclic peptides with pairs of cysteine
residues (defensins, protegrin, etc.), and (iii) peptides with an
overrepresentation of some amino acids (proline-rich, histi-
dine-rich, etc.) [26]. AMPs present a rapid killing and broad-
spectrum antimicrobial activities [27]. AMPs are usually
composed of 12 to 50 amino acid residues, and they show at
least two ormore positively charged residues, generally repre-
sented by arginine, lysine, or histidine, in acid environments,
and with a high content of hydrophobic residues (usually
>50%) [28]. Moreover, most AMPs display hydrophobic and
cationic properties, have a molecular mass below 25–30 kDa,
and adopt an amphipathic structure (alpha-helix, beta-
hairpin-like beta-sheet, beta-sheet, or alpha-helix/beta-sheet
mixed structures) [29]. The ability to associate with the cell
membrane is a key feature of the AMPs, although the mem-
brane permeabilization is not an essential requirement for
their activity [30]. Different peptides act in different ways and
the exact mechanisms are only beginning to be elucidated.
Some intracellular targets have also been described [31]. In
fact, speculations that transmembrane pore formation is not
the only mechanism of microbial killing suggest that translo-
cated peptides can alter cytoplasmic membrane septum
formation, inhibit cell-wall synthesis, inhibit nucleic acid syn-
thesis, inhibit protein synthesis, or inhibit enzymatic activity
[30]. It seems that crotamine is also a potential candidate to be
included in this class of compounds with antimicrobial activ-
ities [32]. More interestingly, it is likely that crotamine and
the well-known AMP defensin could have been derived from
a common ancestor gene [33].This was suggested by Nicastro
and coworkers [1], who first described the similarities of
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the disulfide bonds pattern of these molecules. However,
significant differences in the primary structure/amino acid
composition are observed for these molecules [34]. Despite
the well-known broad antimicrobial spectrum of defensins
[35], crotamine shows a modest activity towards both Gram-
negative and Gram-positive bacteria [36].
Yount and collaborators [33] also suggested the potential
antibacterial and antifungal activity of crotamine. A more
careful determination of minimal inhibitory concentration
(MIC) of crotamine towards a broad range of microorgan-
isms was only recently determined byMirianHayashi’s group
[36]. Crotamine’s important activity against several fungi of
Candida spp., in particular C. albicans, including against
clinical resistant strains, was observed [36]. It is of note that
this Candida species are among the most common blood-
stream pathogens in the United States and rank seventh
among etiologic agents in Europe [37], and the pronounced
effective antifungal activity observed by our group for cro-
tamine opens new perspectives for the use of this venom
component in biomedicine, more specifically for infectious
disease treatments [36].Moreover, someAMPs are also found
to possess translocating activity across the cell membrane,
which can interfere with critical cellular functions leading to
cell death [38]. Similar apoptotic activity in combinationwith
cell penetration was described for crotamine by our group for
several cell types [39]. Moreover, the AMPs are thought to
have other polyanions, such asDNAorRNA, as their ultimate
target [40].
4. Crotamine Anticancer Cells Activity
Actually, it is well accepted that the majority of antimicrobial
compounds might also have antitumor activity [41]. It could
be simply due to the 3D structural similarities or even due to
an evolutionary relationship, which still remains to be deter-
mined [42].The cationic featuremight also be determinant of
both activities [43].The electrostatic interactions between the
negatively charged components of the membrane of cancer
cells and the positively charged peptide are believed to play a
major role in the strong binding of the peptide and its ability
to selectively disrupt the membrane of cancer cells [44].
Investigation of crotamine anticancer cells toxicity and
their in vitro and in vivo efficacy in mouse model of mela-
noma was examined by Kerkis’s group [45, 46]. This toxin at
concentrations of 1–5𝜇g/mL was used to test the viability of
B16-F10 (murine melanoma), SK-Mel-28 (human melanoma
cells), and Mia PaCa-2 (human pancreatic carcinoma cell
line). The nonmalignant neoplastic murine fibroblasts 3T3
cell line was used as control. Interestingly, that crotamine
at final concentration of 5𝜇g/mL was lethal to B16-F10, Mia
PaCa-2, and SK-Mel-28 cells, while it was inoffensive to nor-
mal cells [45]. Additionally, we showed that differently from
several anticancer drugs, crotamine targets primary lysos-
omes and mitochondria, leading to increases of intracellu-
lar free calcium concentrations in cancer cells [16]. Once
the balance of cellular uptake and efflux determines drug
accumulation, we also measured the crotamine permanence
in cancer cells. Using Cy3-crotamine, which was added to
B16-F10 cells, it was possible to observe that at least 70% of
the cells hold the fluorescence signal during approximately
20 h, suggesting a long-term retention of crotamine in these
cells [45]. In vivo, in mouse model for melanoma, crotamine
demonstrates selective penetration into tumor melanoma
cells, predominantly observed within the cells in tumor
masses, in the cells around the tumor necrotic areas, and
in rapidly dividing metastatic cells, but not in normal cells
surrounding the tumors [39, 45].
Fluorescent crotamine traces metastatic invasion of B16-
F10 cells, suggesting its possible applications as an imaging
agent and metastasis marker in living organisms [39].
Delay of melanoma tumors implantation was also
observed after 21 days of chronic treatment with crotamine
(1 𝜇g per animal, per day), in a mice model that received B16-
F10 cells (105 cells) by subcutaneous injection.This treatment,
started at the first day after melanoma cells injection, allowed
to observe that crotamine significantly inhibits the tumor
growth, as evaluated by measuring the tumor mass weight,
and also prolongs the lifespan of these mice bearing B16-
F10 tumor [45]. Histological examination also confirmed that
crotamine is nontoxic to normal cells and normal tissues,
such as kidney and liver, at the used concentrations, as well as
that crotamine does not demonstrate any immunotoxic effect
after in vivo long-term treatment of mice bearing melanoma
tumors [39, 45]. The low immunogenicity of some snake
venom toxins is a well-known feature, which in the case of
crotamine could be attributed to its small size [46].
More recently, using noninvasive optical imaging proce-
dure that permits in vivo real-time monitoring of fluorescent
molecules uptake, crotamine localization into remote subcu-
taneous tumors engrafted in nude mice was confirmed [39].
Additionally, this study also demonstrated that the inhibition
of tumor growth involves mitochondrial depolarization and
intracellular calcium release. These data indicated that the
cytotoxic peptide crotamine could potentially be used for a
dual purpose: to target and detect growing tumor tissues and
also to selectively trigger tumor cell death [39].
Interestingly, infections caused by Candida spp. are fre-
quent and serious in oncology patients [47]. Definitely, a
more precise evaluation of the structure-function relation-
ship for both antimicrobial and antitumor activity of cro-
tamine might allow for the discovery and proposal of poten-
tial novel mechanisms or of new structural models for the
treatment of cancer and/or for the development of a more
selective antimicrobial compounds that might not act on
mammals host cells. Comparative studies to further under-
stand the determinants of antimicrobial and antitumor activ-
ities of crotamine are considered by our group to be highly
significant.
4.1. Crotamine-Like Peptides. Crotamine shares similar struc-
ture features with the defensins, which are a family of small
cysteine-rich cationic proteins found in both vertebrates
and invertebrates. Similarly to crotamine, defensins (from
vertebrates) present a compact structure and consist of 18–
45 amino acid residues, including the presence of six to
eight conserved cysteine residues [48]. Biologically active
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crotamine-like peptides (CLPs) were also described in the
venom of some sauropsid reptiles (lizards and snakes), scor-
pions (Scorpio maurus palmatus), and in small mammals
such as Platypus (Ornithorhynchus anatinus), a semiaquatic
mammal from Eastern Australia [49]. The mechanism of
action of CLPs is very wide, including targets as the voltage-
gated Na+ (Navs) [50], K
+ (Kvs) [51], and acid-sensing ion
channels (ASICs) [52]. Crotamine was also supposed to
present similar effect. In fact, Peigneur et al. [53] reported
that crotamine potently and selectively blocks mammalian
voltage-gated Kv1.3, although it was also demonstrated that
crotamine does not act on Na
(𝑣)
channels [54]. This was the
first study, which shows a neurotoxin from the snakes of
Crotalus genus targeting an ion channel.
5. Conclusions
Indeed, learning more about the way cancer cells is different
from normal cells will allow us to identify and target specific
proteins in cancer cells. Any new treatment proposal aims to
bemore efficient andwith fewer side effects. Since cancer cells
hardly differ physiologically from healthy cells, anticancer
drugs do not specifically affect only cancer cells, but mis-
takenly also affect all other normal dividing cells. Compared
to other known anticancer targeted drugs, only crotamine
was shown to have the ability to selectively target actively
proliferating living cells, both in vitro and in vivo, without
visible effect on normal dividing cells.
Similarly to AMPs, crotamine is highly soluble in water
and is capable of interacting strongly with biological mem-
branes. This might be due to its N-terminal polyarginine
domain, which may allow its interaction with negatively
charged phosphate moieties in the cell membranes, which is
suggestive of a cell-penetrating domain [55]. Crotamine is
also selectively attracted to negatively charged microbial
membranes [36]. Additionally, it presents significant anti-
fungal and antitumor activity [36]. Inside the several cell
types, crotamine interacts with secondary targets, thus being
able to interrupt vital metabolic processes [16]. Moreover, the
recent findings by Peigneur et al. [53] demonstrated that cro-
tamine selectively blocks mammalian Kv1.3, heterologously
expressed in Xenopus laevis oocytes. It also sheds more light
on the possible role of voltage-gated potassium channels
blockage in its anticancer effect, but more studies are still
required to clarify it.
In Table 1, we summarized the possible biotechnological
applications of crotamine and their derivatives. We demon-
strate that crotamine acts differently in normal actively
proliferating (dividing) and cancer cells (Figure 2).This study
provides new insights, which may contribute to unveil the
differences among the normal and cancerous cells using as
a tool the crotamine, which is a versatile and multifunctional
peptide, as described here. On the other hand, crotamine and
their derivates represent already a potential biotechnological
tool. Further studies need to become crotamine derivates
marketable. Although, they are potentially ready to be used
both in vitro and in vivo as molecular carrier, marker of cell
cycle and of centrioles, and as biomarker of cancer cells.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The authors thank the snake for providing the native cro-
tamine for our studies, which is so exciting, interesting, and
valuable. Our studies were supported by the following Brazil-
ian foundations: theNational Council for Scientific andTech-
nologicalDevelopment (CNPq), San PauloResearch Founda-
tion (FAPESP), and the Coordination for the Improvement of
Higher Level or Education-Personnel (CAPES). This work is
dedicated to Dr. Willy Bec¸ak Emeritus Professor of genetics
and the founder of the Laboratory of Genetics, at Butantan
Institute, Sa˜o Paulo, Brazil. Professor W. Bec¸ak is an open
mind and outstanding scientist who inspired several gener-
ation in Brazil with his own exemplar to follow studies in
biology always with high ethical and human pattern.
References
[1] G. Nicastro, L. Franzoni, C. De Chiara, A. C. Mancin, J. R.
Giglio, and A. Spisni, “Solution structure of crotamine, a Na+
channel affecting toxin fromCrotalus durissus terrificus venom,”
European Journal of Biochemistry, vol. 270, no. 9, pp. 1969–1979,
2003.
[2] V. Fadel, P. Bettendorff, T. Herrmann et al., “Automated NMR
structure determination and disulfide bond identification of the
myotoxin crotamine from Crotalus durissus terrificus,” Toxicon,
vol. 46, no. 7, pp. 759–767, 2005.
[3] A. M. Siqueira, N. F. Martins, M. E. De Lima et al., “A pro-
posed 3D structure for crotamine based on homology build-
ing, molecular simulations and circular dichroism,” Journal of
Molecular Graphics and Modelling, vol. 20, no. 5, pp. 389–398,
2002.
[4] M. A. Coronado, A. Gabdulkhakov, D. Georgieva et al., “Struc-
ture of the polypeptide crotamine from the Brazilian rattlesnake
Crotalus durissus terrificus,” Acta Crystallographica D, vol. 69,
pp. 1958–1964, 2013.
[5] G. Ra´dis-Baptista, B. G. de la Torre, and D. Andreu, “Insights
into the uptake mechanism of NrTP, a cell-penetrating peptide
preferentially targeting the nucleolus of tumour cells,”Chemical
Biology and Drug Design, vol. 79, no. 6, pp. 907–915, 2012.
[6] Crotalus durissus terrificus (Laurenti, 1768) Taxonomy ID:
8732.
[7] W. Bec¸ak, M. L. Bec¸ak, H. R. S. Nazareth, and S. Ohno, “Close
karyological kinship between the reptilian suborder serpentes
and the class aves,” Chromosoma, vol. 15, no. 5, pp. 606–617,
1964.
[8] G. Ra´dis-Baptista, T. Kubo, N. Oguiura et al., “Structure and
chromosomal localization of the gene for crotamine, a toxin
from the South American rattlesnake, Crotalus durissus terri-
ficus,” Toxicon, vol. 42, no. 7, pp. 747–752, 2003.
[9] J. M. Gonc¸alves and E. G. Arantes, “Estudos sobre venenos
de serpentes Brasileiras. III-determinac¸a˜o quantitativa de cro-
tamina no veneno de cascavel Brasileira,” Anais da Academia
Brasileira de Cieˆncias, vol. 28, pp. 369–371, 1956.
[10] N. Oguiura, M. E. Camargo, A. R. P. Da Silva, and D. S. P. Q.
Horton, “Quantification of crotamine, a small basic myotoxin,
8 BioMed Research International
in South American rattlesnake (Crotalus durissus terrificus)
venom by enzyme-linked immunosorbent assay with parallel-
lines analysis,” Toxicon, vol. 38, no. 3, pp. 443–448, 2000.
[11] D. L. Cameron and A. T. Tu, “Chemical and functional homol-
ogy of myotoxin a from prairie rattlesnake venom and cro-
tamine from South American rattlesnake venom,” Biochimica
et Biophysica Acta, vol. 532, no. 1, pp. 147–154, 1978.
[12] A. Kerkis, I. Kerkis, G. Ra´dis-Baptista et al., “Crotamine is a
novel cell-penetrating protein from the venom of rattlesnake
Crotalus durissus terrificus,” FASEB Journal, vol. 18, no. 12, pp.
1407–1409, 2004.
[13] I. Kerkis, M. A. F. Hayashi, N. F. Lizier et al., “Pluripotent stem
cells as an in vitromodel of neuronal differentiation,” in Embry-
onic Stem Cells-Differentiation and Pluripotent Alternatives,
Kallos, Ed., pp. 81–98, InTech, Rijeka, Croatia, 2011.
[14] P. C. Chen,M. A.Hayashi, E. B. Oliveira et al., “DNA-interactive
properties of crotamine, a cell-penetrating polypeptide and a
potential drug carrier,” PLoS ONE, vol. 7, no. 11, Article ID
e48913, pp. 1–11, 2012.
[15] G. Ra´dis-Baptista and I. Kerkis, “Crotamine, a small basic poly-
peptidemyotoxin from rattlesnake venomwith cell-penetrating
properties,” Current Pharmaceutical Design, vol. 17, no. 38, pp.
4351–4361, 2011.
[16] M. A. Hayashi, F. D. Nascimento, A. Kerkis et al., “Cytotoxic
effects of crotamine aremediated through lysosomalmembrane
permeabilization,” Toxicon, vol. 52, no. 3, pp. 508–517, 2008.
[17] M. Boni-Mitake,H.Costa, V. S. Vassilieff, and J. R. Rogero, “Dis-
tribution of 125I-labeled crotamine in mice tissues,” Toxicon,
vol. 48, no. 5, pp. 550–555, 2006.
[18] J. P. Blumling III and G. A. Silva, “Targeting the brain: advances
in drug delivery,” Current Pharmaceutical Biotechnology, vol. 13,
no. 12, pp. 2417–2426, 2012.
[19] E. C. de Lange, “The physiological characteristics and transcy-
tosis mechanisms of the blood-brain barrier (BBB),” Current
Pharmaceutical Biotechnology, vol. 13, no. 12, pp. 2319–2327,
2012.
[20] F. D. Nascimento, M. A. F. Hayashi, A. Kerkis et al., “Crotamine
mediates gene delivery into cells through the binding to heparan
sulfate proteoglycans,” Journal of Biological Chemistry, vol. 282,
no. 29, pp. 21349–21360, 2007.
[21] D. Sarko, B. Beijer, R. G. Boy et al., “The pharmacokinetics of
cell-penetrating peptides,” Molecular Pharmaceutics, vol. 7, no.
6, pp. 2224–2231, 2010.
[22] J. Gehl, “Electroporation: theory and methods, perspectives for
drug delivery, gene therapy and research,” Acta Physiologica
Scandinavica, vol. 177, no. 4, pp. 437–447, 2003.
[23] G. M. Poon and J. Garie´py, “Cell-surface proteoglycans as
molecular portals for cationic peptide and polymer entry into
cells,” Biochemical Society Transactions, vol. 35, no. 4, pp. 788–
793, 2007.
[24] D. Jha, R. Mishra, S. Gottschalk et al., “CyLoP-1: a novel
cysteine-rich cell-penetrating peptide for cytosolic delivery of
cargoes,” Bioconjugate Chemistry, vol. 22, no. 3, pp. 319–328,
2011.
[25] F. Schweizer, “Cationic amphiphilic peptides with cancer-
selective toxicity,” European Journal of Pharmacology, vol. 625,
no. 1–3, pp. 190–194, 2009.
[26] N. Boulanger, C. Lowenberger, P. Volf et al., “Characterization
of a defensin from the sand fly Phlebotomus duboscqi induced
by challenge with bacteria or the protozoan parasite Leishmania
major,” Infection and Immunity, vol. 72, no. 12, pp. 7140–7146,
2004.
[27] G. Maro´ti Gergely, A. Kereszt, E´. Kondorosi, and P. Mergaert,
“Natural roles of antimicrobial peptides in microbes, plants and
animals,” Research in Microbiology, vol. 162, no. 4, pp. 363–374,
2011.
[28] Y. Park, S. N. Park, S. Park et al., “Synergism of Leu-Lys rich
antimicrobial peptides and chloramphenicol against bacterial
cells,” Biochimica et Biophysica Acta, vol. 1764, no. 1, pp. 24–32,
2006.
[29] P. Bulet, R. Sto¨cklin, and L. Menin, “Anti-microbial peptides:
from invertebrates to vertebrates,” Immunological Reviews, vol.
198, pp. 169–184, 2004.
[30] K. A. Brogden, “Antimicrobial peptides: pore formers or
metabolic inhibitors in bacteria?”Nature ReviewsMicrobiology,
vol. 3, no. 3, pp. 238–250, 2005.
[31] M. L. Crouch, L. A. Becker, I. S. Bang, H. Tanabe, A. J. Ouellette,
and F. C. Fang, “The alternative sigma factor 𝜎E is required for
resistance of Salmonella enterica serovar Typhimurium to anti-
microbial peptides,” Molecular Microbiology, vol. 56, no. 3, pp.
789–799, 2005.
[32] A. M. S. Mayer, A. D. Rodr´ıguez, R. G. S. Berlinck, and N.
Fusetani, “Marine pharmacology in 2007-8: marine compounds
with antibacterial, anticoagulant, antifungal, anti-inflamma-
tory, antimalarial, antiprotozoal, antituberculosis, and antiviral
activities; Affecting the immune and nervous system, and other
miscellaneous mechanisms of action,” Comparative Biochem-
istry and Physiology C, vol. 153, no. 2, pp. 191–222, 2011.
[33] N. Y. Yount, D. Kupferwasser, A. Spisni et al., “Selective reci-
procity in antimicrobial activity versus cytotoxicity of hBD-2
and crotamine,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 106, no. 35, pp. 14972–14977,
2009.
[34] G. Ra´dis-Baptista, N. Oguiura, M. A. F. Hayashi et al., “Nucle-
otide sequence of crotamine isoform precursors from a single
South American rattlesnake (Crotalus durissus terrificus),” Tox-
icon, vol. 37, no. 7, pp. 973–984, 1999.
[35] G. Maro´ti Gergely, A. Kereszt, E´. Kondorosi, and P. Mergaert,
“Natural roles of antimicrobial peptides in microbes, plants and
animals,” Research in Microbiology, vol. 162, no. 4, pp. 363–374,
2011.
[36] E. S. Yamane, F. C. Bizerra, E. B. Oliveira et al., “Unraveling the
antifungal activity of a South American rattlesnake toxin cro-
tamine,” Biochimie, vol. 95, no. 2, pp. 231–240, 2013.
[37] T. Calandra and O. Marchetti, “Clinical trials of antifungal pro-
phylaxis among patients undergoing surgery,”Clinical Infectious
Diseases, vol. 39, supplement 4, pp. S185–S192, 2004.
[38] G. Kragol, L. Otvos Jr., J. Feng, W. Gerhard, and J. D. Wade,
“Synthesis of a disulfide-linked octameric peptide construct
carrying three different antigenic determinants,”Bioorganic and
Medicinal Chemistry Letters, vol. 11, no. 11, pp. 1417–1420, 2001.
[39] F. D. Nascimento, L. Sancey, A. Pereira et al., “The natural cell-
penetrating peptide crotamine targets tumor tissue in vivo and
triggers a lethal calcium-dependent pathway in cultured cells,”
Molecular Pharmaceutics, vol. 9, no. 2, pp. 211–221, 2012.
[40] Y. Lan, Y. Ye, J. Kozlowska, J. K. W. Lam, A. F. Drake, and A. J.
Mason, “Structural contributions to the intracellular targeting
strategies of antimicrobial peptides,” Biochimica et Biophysica
Acta, vol. 1798, no. 10, pp. 1934–1943, 2010.
[41] D. W. Hoskin and A. Ramamoorthy, “Studies on anticancer
activities of antimicrobial peptides,” Biochimica et Biophysica
Acta, vol. 1778, no. 2, pp. 357–375, 2008.
[42] A. R. Lizzi, V. Carnicelli, M. M. Clarkson, A. Di Giulio, and A.
Oratore, “Lactoferrin derived peptides: mechanisms of action
BioMed Research International 9
and their perspectives as antimicrobial and antitumoral agents,”
Mini-Reviews in Medicinal Chemistry, vol. 9, no. 6, pp. 687–695,
2009.
[43] B. Findlay, G. G. Zhanel, and F. Schweizer, “Cationic amphi-
philes, a new generation of antimicrobials inspired by the nat-
ural antimicrobial peptide scaffold,” Antimicrobial Agents and
Chemotherapy, vol. 54, no. 10, pp. 4049–4058, 2010.
[44] N. Papo and Y. Shai, “Host defense peptides as new weapons in
cancer treatment,” Cellular and Molecular Life Sciences, vol. 62,
no. 7-8, pp. 784–790, 2005.
[45] A. Pereira, A. Kerkis, M. A. Hayashi et al., “Crotamine toxicity
and efficacy in mouse models of melanoma,” Expert Opinion on
Investigational Drugs, vol. 20, no. 9, pp. 1189–1200, 2011.
[46] G. Leo´n, L. Sa´nchez, A. Herna´ndez et al., “Immune response
towards snake venoms,” Inflammation and Allergy-Drug Target-
sno, vol. 10, no. 5, pp. 381–398, 2011.
[47] K. A.Marr, “The changing spectrum of candidemia in oncology
patients: therapeutic implications,” Current Opinion in Infec-
tious Diseases, vol. 13, no. 6, pp. 615–620, 2000.
[48] C. Zhao, T. Nguyen, L. Liu, R. E. Sacco, K. A. Brogden, and R. I.
Lehrer, “Gallinacin-3, an inducible epithelial 𝛽-defensin in the
chicken,” Infection and Immunity, vol. 69, no. 4, pp. 2684–2691,
2001.
[49] B. G. Fry, “From genome to “venome”: molecular origin and
evolution of the snake venom proteome inferred from phylo-
genetic analysis of toxin sequences and related body proteins,”
Genome Research, vol. 15, no. 3, pp. 403–420, 2005.
[50] E. Wanke, A. J. Zaharenko, E. Redaelli, and E. Schiavon,
“Actions of sea anemone type 1 neurotoxins on voltage-gated
sodium channel isoforms,” Toxicon, vol. 54, no. 8, pp. 1102–1111,
2009.
[51] S. Diochot, A. Baron, L. D. Rash et al., “A new sea anemone pep-
tide, APETx2, inhibits ASIC3, a major acid-sensitive channel in
sensory neurons,” EMBO Journal, vol. 23, no. 7, pp. 1516–1525,
2004.
[52] S. Diochot and M. Lazdunski, “Sea anemone toxins affecting
potassium channels,” Progress in molecular and subcellular
biology, vol. 46, pp. 99–122, 2009.
[53] S. Peigneur, D. J. Orts, A. R. Prieto da Silva et al., “Crotamine
pharmacology revisited: novel insights based on the inhibition
of KV channels,” Molecular Pharmacologyno, vol. 82, no. 1, pp.
90–96, 2012.
[54] C. T. Rizzi, J. L. Carvalho-de-Souza, E. Schiavon, A. C. Cas-
sola, E. Wanke, and L. R. P. Troncone, “Crotamine inhibits
preferentially fast-twitching muscles but is inactive on sodium
channels,” Toxicon, vol. 50, no. 4, pp. 553–562, 2007.
[55] M. Rodrigues, A. Santos, B. G. de la Torre et al., “Molecular
characterization of the interaction of crotamine-derived nucle-
olar targeting peptides with lipid membranes,” Biochimica et
Biophysica Actano, vol. 818, no. 11, pp. 2707–2717, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
